General Information of Drug (ID: DMWLZI6)

Drug Name
AZD0466 Drug Info
Indication
Disease Entry ICD 11 Status REF
Hematologic tumour 2B33.Y Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DMWLZI6

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
MCI-186 DM8ZHP1 Amyotrophic lateral sclerosis 8B60.0 Approved [3]
Taxol DMUOT9V Breast cancer 2C60-2C65 Approved [4]
GDC-0199 DMH0QKA Chronic lymphocytic leukaemia 2A82.0 Approved [5]
ABT-263 DMNE56X Myelofibrosis 2A20.2 Phase 3 [6]
Taxol/Paraplatin/Herceptin DML6GAN Breast cancer 2C60-2C65 Phase 3 [7]
Oblimersen DM7KI4E Melanoma 2C30 Phase 3 [8]
RG7601 DMDVAFP Chronic lymphocytic leukaemia 2A82.0 Phase 3 [5]
Thymoquinone DMVDTR2 Polycystic ovarian syndrome 5A80.1 Phase 2/3 [9]
Obatoclax DMPF9ZM Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
PI-88/Taxotere DM4FIWC Solid tumour/cancer 2A00-2F9Z Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ABT-263 DMNE56X Myelofibrosis 2A20.2 Phase 3 [6]
Obatoclax DMPF9ZM Solid tumour/cancer 2A00-2F9Z Phase 2 [10]
APG-1252 DM8O3R9 Small-cell lung cancer 2C25.Y Phase 1/2 [12]
PMID27744724-Compound-18 DM73S2C N. A. N. A. Patented [13]
Indole-based analog 2 DM0NEVC N. A. N. A. Patented [13]
PMID27744724-Compound-10 DMFKS2P N. A. N. A. Patented [13]
PMID27744724-Compound-21 DM18UA5 N. A. N. A. Patented [13]
Indole-based analog 3 DMTEYQJ N. A. N. A. Patented [13]
PMID27744724-Compound-26 DM8GOH3 N. A. N. A. Patented [13]
PMID27744724-Compound-27 DMV6MLC N. A. N. A. Patented [13]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Apoptosis regulator Bcl-2 (BCL-2) TTJGNVC BCL2_HUMAN Inhibitor [2]
Apoptosis regulator Bcl-xL (BCL-xL) TTU1E82 B2CL1_HUMAN Inhibitor [2]

References

1 ClinicalTrials.gov (NCT04865419) Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies. U.S. National Institutes of Health.
2 Design and optimisation of dendrimer-conjugated Bcl-2/x L inhibitor, AZD0466, with improved therapeutic index for cancer therapy. Commun Biol. 2021 Jan 25;4(1):112.
3 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
4 Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res. 2009 Sep 1;69(17):6906-14.
5 ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013 Feb;19(2):202-8.
6 Clinical pipeline report, company report or official report of Roche (2009).
7 Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer. 2005 Dec;6(5):425-32.
8 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.
9 Apoptosis as a mechanism for the treatment of adult T cell leukemia: promising drugs from benchside to bedside. Drug Discov Today. 2020 Jul;25(7):1189-1197.
10 Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis. Clin Lymphoma Myeloma Leuk. 2010 Aug;10(4):285-9.
11 Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer. Ann Oncol. 2010 Jun;21(6):1302-7.
12 Bcl-2/Bcl-xl inhibitor APG-1252-M1 is a promising therapeutic strategy for gastric carcinoma. Cancer Med. 2020 Jun;9(12):4197-4206.
13 Mcl-1 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Feb;27(2):163-178.